<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40793956</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-9159</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>17</Day></PubDate></JournalIssue><Title>International journal of surgery (London, England)</Title><ISOAbbreviation>Int J Surg</ISOAbbreviation></Journal><ArticleTitle>Treatment strategies for patients with ischemic mitral regurgitation: a systematic review and meta-analysis.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/JS9.0000000000003170</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Treatments for ischemic mitral regurgitation (IMR) include coronary artery bypass grafting combined with mitral valve replacement (CABG&#xa0;+&#xa0;MVR), percutaneous coronary intervention (PCI) alone, and PCI combined with transcatheter edge-to-edge repair (TEER), but comparative evidence remains limited. We aimed to systematically evaluate perioperative characteristics, in-hospital and long-term outcomes of these strategies.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">This PRISMA 2020-compliant systematic review and meta-analysis searched PubMed, EMBASE, Web of Science, Cochrane Library, and ClinicalTrials.gov through 12 November 2024. We included studies reporting outcomes for CABG&#xa0;+&#xa0;MVR, PCI alone, or PCI&#xa0;+&#xa0;TEER in IMR, excluding non-human studies, reviews, case reports, editorials, etc. The endpoints included in-hospital/30-day mortality, long-term mortality, cardiovascular mortality, procedural metrics (cardiopulmonary bypass and cross-clamp time), hospital stay, ICU stay, reoperation, readmission, cerebrovascular events, atrial fibrillation, and low cardiac output syndrome (LCOS). Data were pooled using random-effects models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-three studies (1 randomized controlled trial, 32 cohorts; n =&#xa0;3001 patients: 1355 CABG&#xa0;+&#xa0;MVR, 1617 PCI, and 29 PCI&#xa0;+&#xa0;TEER) were analyzed. In-hospital/30-day mortality was 13.8% (95% CI 3.9%-31.7%) for PCI&#xa0;+&#xa0;TEER, 11.8% (95% CI 8.4%-16.5%) for CABG&#xa0;+&#xa0;MVR, and 9.4% (95% CI 7.7%-11.5%) for PCI. Five-year mortality was 37.5% for CABG&#xa0;+&#xa0;MVR vs. 41.8% for PCI. The pooled cardiopulmonary bypass and cross-clamp time for CABG&#xa0;+&#xa0;MVR was 140.2&#xa0;minutes and 101.0&#xa0;minutes, respectively. PCI&#xa0;+&#xa0;TEER had shorter hospital stays (17.3&#xa0;days) than CABG&#xa0;+&#xa0;MVR (22.4&#xa0;days). Hospital/30-day intra-aortic balloon pump rate was lower in CABG&#xa0;+&#xa0;MVR (7.9%) than PCI&#xa0;+&#xa0;TEER (24.1%). 30-day/in-hospital complications included cerebrovascular events (CABG&#xa0;+&#xa0;MVR: 4.1%, PCI: 0.7%), atrial fibrillation (CABG&#xa0;+&#xa0;MVR: 22.9%), and LCOS (CABG&#xa0;+&#xa0;MVR: 19.6%). One-year readmission and 10-year reoperation rates post-CABG&#xa0;+&#xa0;MVR were 7.4% and 31.1%, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">CABG&#xa0;+&#xa0;MVR demonstrated superior long-term survival and lower cardiovascular mortality than PCI but carried higher perioperative risks and complication rates. PCI&#xa0;+&#xa0;TEER showed shorter hospital stays but insufficient data to assess long-term efficacy. Treatment selection requires balancing comorbidities, surgical risk, and MR severity through multidisciplinary decision-making. Robust comparative trials are needed to optimize IMR management.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences, Shenzhen, Guangdong, P.R. China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Research and Biometrics Center, National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College/National Center for Cardiovascular Diseases, Beijing, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Meiling</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences, Shenzhen, Guangdong, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Mingyou</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nutrition, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Weida</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bie</LastName><ForeName>Dongyun</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Xinlin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences, Shenzhen, Guangdong, P.R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Surg</MedlineTA><NlmUniqueID>101228232</NlmUniqueID><ISSNLinking>1743-9159</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">coronary artery bypass</Keyword><Keyword MajorTopicYN="N">ischemic mitral regurgitation</Keyword><Keyword MajorTopicYN="N">mitral valve replacement</Keyword><Keyword MajorTopicYN="N">percutaneous coronary intervention</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">transcatheter edge-to-edge repair</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>12</Day><Hour>12</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>12</Day><Hour>12</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>12</Day><Hour>10</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40793956</ArticleId><ArticleId IdType="doi">10.1097/JS9.0000000000003170</ArticleId><ArticleId IdType="pii">01279778-990000000-02963</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>